IOV-4001
- Generic Name
- IOV-4001
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Unresectable MelanomaStage III Non-small Cell Lung CancerMetastatic MelanomaStage IV Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT05361174
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Orlando Health Cancer Institute, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath